Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences to present at Baird’s Global Healthcare Conference and Lake Street Best Ideas Growth Conference.
09/05/2023 - 07:00 AM
FRIENDSWOOD, Texas --(BUSINESS WIRE)--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2023 Global Healthcare Conference on Wednesday, Sept. 13, 2023, at 10:15 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx . A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the 7th Annual Lake Street Best Ideas Growth (BIG7) Conference on Sept. 14, 2023. Meetings may be requested exclusively through Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CMSeq , DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq , TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905299326/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
CSTL Rankings
#4637 Ranked by Stock Gains
CSTL Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Health Services, Medical/Nursing Services
About CSTL
castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
